Mertin J, Rudge P, Kremer M, Healey M J, Knight S C, Compston A, Batchelor J R, Thompson E J, Halliday A M, Denman M, Medawar P B
Lancet. 1982 Aug 14;2(8294):351-4. doi: 10.1016/s0140-6736(82)90547-5.
In a double-blind controlled trial 43 patients with relapsing-remitting multiple sclerosis were treated either with anti-lymphocyte globulin, prednisolone, and azathioprine, or with placebo preparations. Treatment began with a combination of the three medicaments but after 1 month was continued for another 14 months with azathioprine (3 mg/kg dialy) only. There was a marginally beneficial effect of immunosuppression on the overall relapse rate and clinical progression. However, there were significant effects on in-vitro lymphocyte function and in the visual evoked potentials in favour of the group receiving suppressive treatment. Placebo-treated patients of the HLA A3 tissue type had significantly more relapses than placebo-treated patients who were not of type HLA A3. Nevertheless, HLA-A3-positive patients treated with immunosuppression had significantly fewer relapses than A3-positive placebo-treated patients.
在一项双盲对照试验中，43例复发缓解型多发性硬化症患者接受抗淋巴细胞球蛋白、泼尼松龙和硫唑嘌呤治疗，或接受安慰剂制剂治疗。治疗开始时使用这三种药物的组合，但1个月后仅继续使用硫唑嘌呤（每日3mg/kg）治疗另外14个月。免疫抑制对总体复发率和临床进展有轻微有益作用。然而，对体外淋巴细胞功能和视觉诱发电位有显著影响，有利于接受抑制治疗的组。HLA A3组织类型的安慰剂治疗患者比非HLA A3类型的安慰剂治疗患者有更多的复发。然而，接受免疫抑制治疗的HLA - A3阳性患者比接受安慰剂治疗的A3阳性患者复发明显更少。
